Gut microbiota and IgA shape vaccine effectiveness. Disrupted mucosal immunity may reduce response, guiding clinicians to evaluate nonresponse, personalize vaccination, and protect vulnerable populations.

Patient-centered integration of spirituality into substance use care can enhance prevention and recovery, provided boundaries, autonomy, and evidence-based treatments remain central to clinical decision making.

Emerging evidence links sleep disruption to microglial activation, connecting fragmented sleep with inflammation, cognitive impairment, mood symptoms, and potential long-term neurodegenerative vulnerability, reframing insomnia as neuro-immune stress.

COVID-19 mRNA vaccination near immunotherapy initiation may enhance cancer survival by reprogramming tumor immunity, potentially transforming “cold” tumors and reshaping oncology practice, policy, and research priorities.

Rising rheumatology article retractions, largely driven by misconduct, threaten evidence integrity, clinical decision making, patient safety, and trust in research guiding lifelong autoimmune disease treatment.

Off-label therapies for alopecia areata expand options beyond approved treatments, balancing access, safety, monitoring, and equity while evidence gaps complicate shared decision making and long-term outcomes.

Administrative barriers and benefit design delays in metabolic care restrict access to GLP-1 and incretin therapies, worsening diabetes and obesity outcomes while widening equity gaps.

Healthy aging prioritizes function, independence, and dignity through routine functional assessment, deprescribing, fall prevention, sensory support, caregiver engagement, and team-based, community-connected care aligned with patient goals.

Long-term data show some irritable bowel syndrome patients later develop inflammatory bowel disease, underscoring risk-stratified follow-up, red flag recognition, and targeted testing to prevent delayed diagnosis.

Acute optic neuritis demands rapid escalation to plasma exchange in high-risk or steroid-refractory patients, preserving vision by removing pathogenic antibodies before irreversible optic nerve damage occurs.